The US Food and Drug Administration published a final guidance document 8 September to aid industry in preparing premarket applications (PMAs), humanitarian device exceptions (HDEs), investigational device applications (IDEs), premarket notifications (510(k)s), and de novo requests.
The guidance seeks to help sponsors submitting these applications to determine the potential for an adverse biological response that may occur when various materials from the subject device contact the...